Inscripta Hires Chief Commercial Officer Jason T. Gammack to Bring Gene-Editing Tools to Market

News provided by

Nov 01, 2018, 12:37 ET

BOULDER, Colo., Nov. 1, 2018 /PRNewswire/ -- Inscripta™, a leading gene-editing technology company, today announced the addition of Jason T. Gammack as the company's first chief commercial officer. Gammack, a 25-year veteran of life sciences commercial operations, will leverage his experience at leading biotechnology companies to design and oversee Inscripta's sales, marketing, business development, and customer support operations.

"We are assembling an elite team to develop, build, and provide our innovative gene-editing portfolio to customers, and Jason brings outstanding experience that will ensure these essential tools help researchers unlock the next age of genetic discovery," said Kevin Ness, CEO of Inscripta. "He is known as a trailblazing executive with a track record of building strong sales and marketing operations for some of the most important life science companies in the industry. Jason is a truly inspiring leader and Inscripta is fortunate to have him join our team."

Gammack has spent his entire career developing product and commercial strategies for some of the life science industry's most preeminent brands. He was most recently at QIAGEN, where he led the development of the life science portfolio and go-to-market strategy as the vice president of the life science business area. Prior to QIAGEN, Gammack developed commercialization growth strategies as an executive at Ingenuity Systems, a leading bioinformatics company acquired by QIAGEN in 2013. He has also held senior leadership roles at Sigma-Aldrich (SIAL), Life Technologies (LIFE), Affymetrix (AFFX), and Promega Corporation.

"Simply put, Inscripta's platform is the holy grail of biology. Our groundbreaking technology will allow researchers to ask fundamental biological questions never before thought possible," said Gammack. "To realize the disruptive potential of the platform, we will focus on two significant levers: content and community. I'm thrilled to have the opportunity to apply my experience to the most significant scientific development of my lifetime: genome writing."

The addition of Gammack is the latest landmark in Inscripta's growth. The company recently completed a strategic acquisition of Solana Biosciences, a company made up of the former Illumina operations team that guided the launch and production of hundreds of life sciences products. Inscripta also raised $55.5 million in its Series C funding round from leading industry investors including Venrock, Mérieux Développement and Paladin Capital Group to continue development of its unique family of CRISPR enzymes (MADzymes) and to grow its product offering for a full suite of gene-editing tools with improved capabilities for multiple genome-editing applications.

ABOUT INSCRIPTA
Inscripta is a gene-editing technology company that puts researchers in control by making it easy for them to get all they need for cutting-edge, forward cell-engineering. These tools include a family of CRISPR enzymes (called MADzymes), custom nucleases for researchers and commercial partners, and a full suite of gene-editing tools (instruments, reagents, and software) that will significantly increase the speed and efficiency of multiplexed, precision gene editing. By removing the barriers to forward cell-engineering and gene-editing research, Inscripta will usher in a new era of advances to revolutionize how we feed, fuel, and heal humanity.

Inscripta is led by several genomic technology veterans including CEO Kevin Ness, who co-founded QuantaLife and 10x Genomics, and John Stuelpnagel, the chairman of the company's board, who was co-founder and first CEO of Illumina (ILMN) and chairman of 10x Genomics. Inscripta is headquartered in Boulder, Colo.; has offices in Pleasanton, Calif. and San Diego; and is backed by Venrock, MLS Capital, NanoDimension, Foresite, Paladin Capital Group, and Mérieux Développement. For more information, visit: www.inscripta.com.

SOURCE Inscripta